Center-Authored Papers

Filters: Author is Yee, C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yee C.  2010.  Adoptive therapy using antigen-specific T-cell clones.. Cancer journal (Sudbury, Mass.). 16(4):367-73. Abstract
Yee C.  2007.  Adoptive Cellular Therapy of Cancer. General Principles of Tumor Immunotherapy Basic and Clinical Applications of Tumor Immunology. :343-361.
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD.  2002.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.. Proceedings of the National Academy of Sciences of the United States of America. 99(25):16168-73. Abstract
Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD.  1999.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.. Journal of immunology (Baltimore, Md. : 1950). 162(4):2227-34. Abstract
Yee C.  2006.  Adoptive T-cell therapy of cancer.. Hematology/oncology clinics of North America. 20(3):711-33. Abstract
Yee C, Greenberg P.  2002.  Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.. Nature reviews. Cancer. 2(6):409-19.
Yee C.  2005.  Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.. Journal of translational medicine. 3(1):17. Abstract
Yee C.  2014.  The use of endogenous T cells for adoptive transfer.. Immunological reviews. 257(1):250-63. Abstract
Yee C.  2011.  Tumor Immunotherapy. The Molecular Biology of Cancer.
Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD.  1996.  Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.. Journal of immunology (Baltimore, Md. : 1950). 157(9):4079-86. Abstract
W
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C.  2011.  White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(7):1664-73. Abstract
Wallen H, Thompson JA, Reilly ZJ, Rodmyre RM, Cao J, Yee C.  2009.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.. PloS one. 4(3):e4749. Abstract
T
Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M.  2011.  Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.. Gene therapy. 18(8):827-34. Abstract
S
Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR et al..  2014.  Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment.. PloS one. 9(5):e96565. Abstract
Shah KV, Chien AJ, Yee C, Moon RT.  2008.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.. The Journal of investigative dermatology. 128(12):2870-9. Abstract
R
Robins HS, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson CS, Nepom G, Yee C, Cerosaletti K.  2012.  Ultra-sensitive detection of rare T cell clones.. Journal of immunological methods. 375(1-2):14-19. Abstract
P
Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.. PloS one. 7(2):e32165. Abstract
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M et al..  2014.  Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.. Journal for immunotherapy of cancer. 2(1):36. Abstract
Pollack SM, Yee C.  2011.  Innate Immune Regulation and Cancer ImmunotherapyAdoptive Immunotherapy of Melanoma. :439-465.
Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL.  2011.  Immune-based therapies for sarcoma.. Sarcoma. 2011:438940. Abstract
Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.. Cancer. 118(18):4564-70. Abstract
Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N et al..  2018.  Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.. Nature communications. 9(1):3868. Abstract
N
Noh KH, Kim S-H, Kim JH, Song K-H, Lee Y-H, Kang TH, Han HD, Sood AK, Ng J, Kim K et al..  2014.  API5 Confers Tumoral Immune Escape through FGF2-Dependent Cell Survival Pathway.. Cancer research. 74(13):3556-66. Abstract
L
Lim SA, Kim T-J, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi I-K, Yun C-O, Kim J-H et al..  2013.  Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.. Cancer research. 73(8):2598-607. Abstract
Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C.  2004.  Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.. Molecular therapy : the journal of the American Society of Gene Therapy. 9(5):757-64. Abstract